Innovative MedTech, Inc. has completed its planned corporate rebranding and name change to AnTix Holdings, Inc., marking a fundamental shift in the company's strategic direction. The change better aligns with the company's expansion into the growing online ticketing and entertainment technology sector, where it plans to apply artificial intelligence and Web 3.0 tools to improve the ticketing and live experience for consumers and partners.
Michael J. Friedman, President and CEO of AnTix Holdings, Inc., stated that this rebranding represents an exciting milestone for the company. The transition comes as the company's ticketing technology has begun generating revenues, providing what management believes will be a strong foundation for the next phase of growth. The company's goal is to build value through innovation, execution and acquisition in a market that Friedman described as ripe for significant technological change.
The corporate name change was formally executed on September 19, 2025, when the company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the State of Delaware. While the corporate name has changed from Innovative MedTech, Inc. to AnTix Holdings, Inc., the company's common stock will continue to trade under the ticker symbol IMTH for the time being. The company intends to file with FINRA to effectuate both the name change and a change to a new ticker symbol.
This strategic pivot is significant because it represents a complete transformation of the company's core business focus from medical technology to entertainment technology. The move positions AnTix Holdings to capitalize on what management sees as meaningful opportunities in the online ticketing space, particularly through the application of artificial intelligence. The company's mission now centers on bringing transparency, efficiency and personalization to the ticketing and entertainment industry.
Despite the fundamental business model shift, the company maintains its connection to its medical technology roots through its exclusive licensing arrangement for the Oral Thrush application of Shear Kershman Labs' BioViscid™ bio-adhesive encapsulation. This dual focus suggests the company may be maintaining some diversification while primarily pursuing growth in the ticketing technology sector. For more information about the company's new direction and technology offerings, visit https://www.antixholdings.com.
The rebranding and strategic shift come with inherent risks and uncertainties, as noted in the company's Safe Harbor Statement. These include general economic conditions, market competition, the ability to secure capital, and uncertainty about whether the company's strategies and business plans will yield the expected benefits. The success of this pivot will depend on the company's ability to execute its vision in a competitive market while navigating the challenges of fundamentally changing its business identity and operations.
